Senses Disorder TRIZ Cases

Laminin-coated culture and replating improve RPE cell purity, scale-up, and quality control using surface markers.

Targets continuous IL-33 epitopes while keeping germline framework regions intact to reduce antigenicity and sustain neutralizing efficacy.

An Fc-IgG anti-VEGF fusion adds heparin-binding to extend vitreous residence time, reducing injection frequency in ocular angiogenic disorders.

Using HPH-15 to activate AMPK, this case shows a lower-dose way to control blood glucose and reduce fat accumulation with fewer side effects.

An Fc-linked VEGF binder using VEGFR-1 IgG-like domains extends intraocular half-life, reducing injection frequency while sustaining anti-angiogenic effect.

Capsid amino acid substitutions improve retinal cell transduction while reducing neutralizing antibody impact in ocular gene therapy.

Targeted FAM161A vector expression in the photoreceptor connecting cilium helps restore retinal anatomy, function, and visual acuity.

Using raw milk instead of processed sources preserves lactoferrin conformation, iron-binding capacity, and purity for animal wound care and infection control.

Small-molecule C1s inhibitors modulate complement activation to limit synapse loss and slow neurodegenerative disease progression.

Optimized excipients and granulation processes help Compound 1 tablets maintain hardness while improving dissolution and consistent oral availability.

Targeted Sema3A neutralization with antibodies helps overcome axonal growth inhibition and improve CNS nerve regeneration after injury.

Peptide inserts in AAV capsids improve inner limiting membrane penetration and enable pan-retinal gene delivery after intravitreal injection.

Targeted C7-substituted oxysterols tune NMDA receptor activity to improve CNS and psychiatric treatment specificity while limiting side effects.

Hydroxamic acid derivatives improve selective inhibition of astacin proteinases while limiting off-target ADAM and MMP effects.

Fermented herbal extracellular vesicles combine polysaccharides and β-NMN to protect the optic nerve and support retinal and ganglion cell repair.

Selective RIPK1 inhibitor compounds modulate inflammation and apoptosis to address diseases driven by excessive cell death signaling.

Using mesenchymal stem cell exosomes instead of direct cell therapy helps protect retinal cells while avoiding fibroblast-related safety risks.

Modified TATA and CAAT box promoters enable recombinant viruses to express genes selectively in hyperproliferative cells while sparing normal cells.

A ligand-responsive riboswitch cassette controls alternative splicing to switch target gene expression on with precise timing and up to 1687-fold induction.

Histidine, Tween 80, and heparin sodium stabilize acidic fibroblast growth factor eye drops for 9 months at room temperature.

Multiple nucleic acid vectors recombine in mammalian cells to restore full-length stereocilin expression and address genetic hearing loss.

Engineered VR2.0 improves retinal optogenetics by combining high photosensitivity, fast kinetics, and stable photocurrents under rapid stimulation.

A lactic acid bacteria composition activates pDCs and interferon production to help prevent or treat post-COVID taste and smell disorders.

Topical ranpirnase in an aqueous eye formulation lowers adenoviral titer and relieves symptoms without causing irritation.

A hydrogel contact lens holds and slowly releases therapeutic agents on the eye, extending tear-film residence and reducing repeat dosing.

Isolated exogenous mitochondria are delivered to the eye to restore retinal energy supply, reduce oxidative stress, and support corneal healing.

A selective PDGF receptor kinase inhibitor composition suppresses pulmonary arterial smooth muscle growth while reducing erythroid colony suppression.

Engineered Fc variants coengage FcγRIIb and CD19 on B cells to suppress activation and reduce IgG4-related disease symptoms.

Targeting HPTPβ with a monoclonal antibody reduces ocular vascular leakage and neovascularization in recurrent retinal diseases.

Novel hTRPM1 promoter elements improve ON-bipolar cell targeting and expression strength for retinal gene therapy and vision restoration.

A 4-phenylpiperidine compound lowers retinal bisretinoids by partially inhibiting the visual cycle while preserving photoreceptor function.

Selective AQP4 and AQP2 phenylbenzamide inhibitors block water transport to reduce cerebral edema and improve targeted fluid-balance treatment.

A strong acceptor splice region improves trans-splicing reconstitution of split coding sequences in AAV gene therapy vectors.

A histidine acetate buffered antibody formulation balances high concentration, stability, isotonicity, and low viscosity for intravitreal use.

By linking IL-4 or IL-13 targeting moieties with Bcl-2 family proteins, this case improves cell survival while limiting toxicity and uptake barriers.

AAV vectors deliver BMI1 to retinal cells through ocular injection, improving cell function and reducing retinopathy-related vision loss.

Mucoadhesive chitosan nanoparticles retain PDRN on the ocular surface for controlled release, improving bioavailability with less frequent dosing.

Local intravitreal or topical DHODH delivery treats ocular inflammation while avoiding liver toxicity and other systemic side effects.

An engineered oral SOD from a GRAS bacterium targets retinal oxidative stress to reduce drusen and help treat dry macular degeneration.

Small C3-binding antibody fragments penetrate Bruch's membrane to inhibit complement pathways and reduce geographic atrophy lesion growth.

A buffered pH 5.5-7.0 formulation with stabilizer and surfactant limits bispecific antibody aggregation and preserves anti-neovascularization efficacy.

Nicotinamide and pyruvate help lower intraocular pressure while protecting retinal ganglion cells from glaucoma-related neurodegeneration.

A trehalose, mannitol, and hydroxypropylmethyl cellulose eye formulation promotes corneal epithelial healing beyond lubrication alone.

Phosphate salt prodrugs improve aquaporin inhibitor solubility and stability, enabling rapid administration for edema and hyponatremia.

Reduced-IGFBP-binding IGF-1 variants improve meibomian gland size, lipid content, and local durability for MGD treatment.

An inflammation-inducible ocular gene vector enables local anti-TNF expression to control uveitis while reducing systemic adverse effects.

Ellagitannin precursors and urolithins raise autophagy through lysosomal degradation, supporting longevity and healthier aging outcomes.

A phosphorylcholine-tuftsin conjugate reduces ocular inflammation by modulating cytokines, enabling lower steroid doses with fewer side effects.

A fusion AAV capsid combines AAV1, AAV2, AAV6, and AAV7 fragments to improve cochlear and retinal targeting while reducing non-specific infection.

Small-molecule stilbene derivatives bind aggregated proteins to inhibit or reverse aggregation in CNS, ocular, and related disorders.

An immunogenic composition combines pathogen-associated molecular patterns with danger signals to activate sentinel cells and drive adaptive immunity.

Vinca alkaloid N-oxides resolve hypoxia resistance by selectively activating in low-oxygen tumor regions, reducing systemic toxicity.

Offsetting the deck from ribs via connecting walls reduces thermomechanical stresses and parasite drag while enabling lighter materials.

Codon optimization of the RPGR ORF15 sequence eliminates mutagenic regions, preventing vector instability and maintaining photoreceptor cell function.

A dry eye composition combines alginate with polyols to provide prolonged ocular surface relief.

Substituted dibenzonaphthacene compounds enable efficient vapor deposition and solution processing for organic light emitting diodes.

Retinal cell suspension stabilized with DMSO and fetal bovine serum extends viability duration beyond days by enabling cryogenic preservation.

Modified himbacine derivatives block thrombin and CB2 receptors, resolving specificity limits in treating thrombotic and inflammatory diseases.

A biodegradable polymer fiber remodels into a depot to sustain bioactive agent release, reducing injection frequency for posterior segment eye treatments.

Mutant neuroserpin resists oxidative inactivation to inhibit plasmin activity and protect retinal ganglion cells from degeneration.

Preservative-free atropine ophthalmic composition uses a low-strength buffer system to maintain pH between 5.0 and 6.0.

N-acylpeptide derivatives modify peptide hydrophobicity to enhance skin penetration and bioavailability.

Targeting ligands bind retinal proteins to resolve the trade-off between non-viral safety and transfection efficiency in ocular gene therapy.

Escin inhibits granulocyte activation and TNF-alpha production, avoiding side effects from corticosteroids.

Bioerodible implants deliver latanoprost to reduce iris pigmentation and hyperemia while maintaining therapeutic efficacy.

Copolymer-1 redirects harmful microglial inflammation into neurogenesis, halting age-related macular degeneration progression.

Specific peptide markers enable precise grass species identification in complex compositions.

Genetic marker testing identifies dry eye patients likely to respond favorably to TNF alpha antagonist treatment, avoiding ineffective steroid use.

Disulfide bonds stabilize recombinant tenascin C scaffolds, resolving antibody aggregation and immunogenicity trade-offs while maintaining high affinity.

Polydopamine nanoparticles release anti-VEGF agents via redox-responsive degradation, addressing side effects from repeated injections in wet AMD treatment.

D-amino acid peptide amides selectively activate kappa receptors to provide analgesia while avoiding respiratory depression and addiction risks.

Cationic liposomes complex with toll-like receptor ligands to adhere to mucosal surfaces, reducing antibiotic resistance and adverse effects.